Recruiting
Selective Sentinella Lymph Node Biopsy with Indocyanine Green in Patients with Breast Cancer
The current observational study aims to perform the sentinel lymph node in breast cancer in the usual way with technetium 99 and add a second tracer, indocyanine green. The objective is to evaluate the detection rate of the lymph node with indocyanine green compared to the usual technique.
ClinicalTrials.gov IDNCT06378944
PhaseNot Applicable
Enrollment15000
SponsorOmphis Foundation
Age18 Years
SexALL
Conditions studied
Breast Cancer
About this study
The current observational study aims to perform the sentinel lymph node in breast cancer in the usual way with technetium 99 and add a second tracer, indocyanine green. The objective is to evaluate the detection rate of the lymph node with indocyanine green compared to the usual technique.
Interventions
- Other: Application of green indocyanine colorant — The day of the surgery 1 ml of green indocyanine colorant will be applicated periareolar. After 5 minutes the lymph node will be detected and extracted
- Drug: Technetium99 — Application of a periareolar injectionof TEchnetium 99 in order to detect the axillary lymph node
Primary outcomes
- Number of Sentinel lymph node detected. Scale of numbers (patients included from 1 January of 2024 til January 1 2029)
Eligibility information
Inclusion Criteria:
* Patients \>18 years of age with breast cancer who are candidates for sentinel lymph node detection will be included.
* N0 patients or patients who have undergone target axillary detection with good response
Exclusion Criteria:
* Lymphadenectomy
Study locations
- Sandra Lopez Gordo, Cerdanyola del Vallès, Barcelona 08290 Spain
Before you participate: Varda Clinical is an independent discovery tool, not the study sponsor or a medical provider. Eligibility can only be determined by the official study team. Discuss potential risks and benefits with a qualified healthcare professional.
Source: ClinicalTrials.gov. Record last refreshed by Varda Clinical: 2026-09-30.